AI Article Synopsis
Article Abstract
Background: Primary hepatic neuroendocrine tumors (PHNETs) are rare, accounting for approximately 0.3 % of all neuroendocrine tumors (NETs) and are often difficult to diagnose due to their nonspecific symptoms and imaging features. Standard diagnostic and treatment protocols are lacking due to their rarity, but imaging and immunohistochemistry (IHC) remain key tools for diagnosis.
Case Report: A 68-year-old male presented with abdominal discomfort and loss of appetite. Imaging revealed a large exophytic mass in the left lobe of the liver. After ruling out extrahepatic primary sources, a left lobe hepatectomy was performed. Histopathology confirmed the diagnosis of PHNET, with positive IHC staining for synaptophysin and CK-7. Postoperative PET-CT ruled out any distant metastases. The patient had an uneventful recovery.
Discussion: PHNETs are believed to originate from ectopic neuroendocrine cells in the liver, though several theories exist. Imaging alone cannot conclusively diagnose PHNETs, as they mimic other hepatic tumors like hepatocellular carcinoma. Histopathological examination, along with IHC markers like chromogranin and synaptophysin, is essential for diagnosis. Surgical resection remains the treatment of choice, with good outcomes despite the risk of recurrence. Non-surgical therapies, such as chemotherapy or ablation, are under investigation but lack consensus.
Conclusion: PHNETs are rare and challenging to diagnose, requiring imaging and IHC for confirmation. Surgery offers the best prognosis, making personalized, surgery-centered treatment plans essential for management. Comprehensive follow-up, including functional imaging, is necessary to monitor recurrence or metastasis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11638599 | PMC |
| http://dx.doi.org/10.1016/j.ijscr.2024.110647 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
CT-based liver peritumoral radiomics features predict hepatic metastases sources as gastrointestinal or non-gastrointestinal.
Br J Radiol
December 2024
Department of Radiology, Northern Jiangsu People's Hospital, Northern Jiangsu People's Hospital Affiliated to Yangzhou University, Yangzhou, China.
Objectives: To investigate the feasibility of radiomics models for predicting the source of hepatic metastases from gastrointestinal (GI) vs. non-gastrointestinal (non-GI) primary tumors on contrast enhanced CT(CECT).
Methods: 347 patients with liver metastases (180 from GI and 167 from non-GI) and abdominal CECT including arterial, portal venous, and delayed phases were divided into training (221) and validation (96) sets at a ratio of 7:3 and an independent testing set (30).
Drug-induced hepatic sinusoidal obstruction syndrome: current advances and future perspectives.
Arch Toxicol
December 2024
Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, China.
Hepatic sinusoidal obstruction syndrome (HSOS) has gained recognition as a rare form of drug-induced liver injury (DILI) in recent years. Although extensively studied in the context of hematopoietic stem cell transplantation (HSCT), the applicability of this knowledge to drug-induced HSOS remains limited due to distinct etiological factors. The primary causes of drug-induced HSOS include the ingestion of pyrrolizidine alkaloid (PA)-containing plants, as well as the use of chemotherapeutic agents and immunosuppressive drugs.
View Article and Find Full Text PDFThe fungicide propiconazole induces hepatic steatosis and activates PXR in a mouse model of diet-induced obesity.
Arch Toxicol
December 2024
Nutrition, Metabolism and Genomics Group, Division of Human Nutrition and Health, Wageningen University, Wageningen, The Netherlands.
Propiconazole is a triazole fungicide previously shown to induce triglyceride accumulation in human liver HepaRG cells, potentially via activation of the Pregnane X Receptor (PXR). However, whether propiconazole can disrupt hepatic and whole-body metabolism in vivo is currently unknown. Therefore, we aimed to examine the metabolic effects of propiconazole in the context of metabolic dysfunction-associated steatotic liver disease (MASLD), obesity, and insulin resistance.
View Article and Find Full Text PDFPrimary Care Screening for Nonalcoholic Fatty Liver Disease Among People With HIV in the United States: A Real-World Provider Survey.
J Assoc Nurses AIDS Care
December 2024
Jennifer C. Price, MD, PhD, is a Professor, Division of Gastroenterology and Hepatology, University of California San Francisco, San Francisco, California, USA. Kyoko Hirose, BA, is a Research Coordinator, Division of Gastroenterology and Hepatology, University of California San Francisco, San Francisco, California, USA. Naga Chalasani, MD, is a Professor, Division of Gastroenterology and Hepatology, Indiana University School of Medicine, Indianapolis, Indiana, USA. Holly Crandall, RN, BSN, CCRP, is a Project Manager, Division of Gastroenterology and Hepatology, Indiana University School of Medicine, Indianapolis, Indiana, USA. Sonya Heath, MD, is a Professor, Division of Infectious Diseases, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA. Rohit Loomba, MD MHSc, is a Professor, Division of Gastroenterology and Hepatology, University of California, San Diego, California, USA. Susanna Naggie, MD, is a Professor, Duke Clinical Research Institute, Duke University, Durham, North Carolina, USA. Richard K. Sterling, MD, MSc, is a Professor, Division of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University, Richmond, Virginia, USA. Mark Sulkowski, MD, is a Professor, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Laura Wilson, ScM, is a Senior Research Associate, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA. Jordan E. Lake, MD, MSc, is an Associate Professor, Division of Infectious Disease, University of Texas Health Sciences Center at Houston, Houston, Texas, USA.
Nonalcoholic fatty liver disease (NAFLD) is highly prevalent in people with HIV (PWH) and increases the risk of hepatic fibrosis and hepatocellular carcinoma. We sent an online survey to providers of the American Academy of HIV Medicine. Of respondents (n = 214, 8% response rate), 65% reported screening for NAFLD in PWH, with 28% routinely screening all patients.
View Article and Find Full Text PDFHepatocellular carcinoma hosts cholinergic neural cells and tumoral hepatocytes harboring targetable muscarinic receptors.
JHEP Rep
January 2025
Hepatitis Viruses and Pathobiology of Chronic Liver Diseases - LabEx DEVweCAN, Inserm U1052, Cancer Research Centre of Lyon - Hepatology Institute of Lyon F - IHU EVEREST, University of Lyon 1, ISPB, France, CNRS UMR5286, Centre Léon, Lyon, France.
Background & Aims: Owing to unexplained interpatient variation and treatment failure in hepatocellular carcinoma (HCC), novel therapeutic approaches remain an urgent clinical need. Hepatic neurons, belonging to the autonomic nervous system (ANS), mediate liver/whole body crosstalk. Pathological innervation of the ANS has been identified in cancer, nurturing tumor stroma and conferring stronger carcinogenic properties.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!